7 Moments That Transformed the Obesity Device Market

  • When the American Medical Association officially recognized obesity as a disease in 2013, it caused a shift and renewed vigor in  medtech solutions for the condition. Here are seven key events that transformed the device obesity treatment space. 

  • Aspire Nabs FDA Nod

    Aspire Bariatrics made a huge splash in the market in 2016, riding the wave of FDA approvals that occurred a year prior in the obesity treatment space. The King of Prussia, PA-based company received FDA approval for an endoscopic device that prevents extra calories from being absorbed by the body.

    Leunert/Pixabay
  • Medtronic Introduces GastriSail

    In 2015, Medtronic launched the GastriSail Unit. The Dublin-based company inherited the bariatric surgical solution when it acquired Covidien for $43 billion. The GastriSail system combines the benefits of three devices into one, allowing surgeons to consistently size and decompress the stomach pouch and test for leaks without removing and reinserting another device. However, a Class 2 recall was recently announced for the device.

     

    TeroVesalainen/Pixabay
  • Approval Starts the Reshaping of the Obesity Market

    ReShape Medical received a significant approval in the obesity treatment space when it won a PMA for its dual balloon for nonsurgical weight loss for patients in 2015. The San Clemente, CA-based company’s FDA nod set off a domino effect that led to consolidation in the market and the company's eventual transformation.

    3D_manEU/Pixabay
  • EnteroMedics Picks Up Bariosurg

    In May of last year, EnteroMedics sought to strengthen its position in the obesity treatment market and picked up Lake Forest, CA-based Bariosurg. From the acquisition, EnteroMedics was able to obtain the Gastric Vest, a minimally invasive, laparoscopically implanted device to treat obesity. It would not be EnteroMedics last acquisition in the space. 

    TheDigitalArtist/Pixabay
  • EnteroMedics and ReShape Merge

    A few months after EnteroMedics made a play to acquire Bariosurg, it made a proposal to pick up ReShape Medical. The St. Paul, MN-based company proved it had been paying attention to the market and snapped up ReShape soon after the approval of the ReShape Dual Weight Loss Balloon. The company even changed its name to ReShape Lifesciences.

    RawPixel/Pixabay
  • GI Dynamics Loses CE Mark, But is the Company Headed for a Comeback?

    It should be mentioned from the start that GI Dynamics' Endobarrier is used to treat Type 2 Diabetes in patients.  Technically it’s not a device that solely treats obesity. However, the device does impact patients with obesity and is a flexible, tube-shaped liner that forms a shield between food and part of the intestinal wall letting food bypass the duodenum in a nonsurgical alternative to gastric bypass surgery. The company has struggled in the past few years. It lost its CE mark for the device in Nov. of 2017. Prior to losing its CE mark, FDA halted the company’s U.S. pivotal ENDO trial after four cases of hepatic abscess were found among the 325 patients enrolled in the trial. GI Dynamics had been quiet for months but in March the firm began making noise when its shareholders recently approved an offering of $2 million. Could the offering lead to the company's resurgence?

  • Apollo’s Big Play
    Apollo Endosurgery picked up both the Orbera balloon and the Lap-Band device through its $110 million acquisition of Allergan's obesity intervention division in 2013. This has been one of the most significant, not to mention largest acquisitions in the obesity treatment space in recent years. Apollo also set the tone for the obesity treatment market with the acquisition.

Filed Under
500 characters remaining